Compare TNC & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNC | RLAY |
|---|---|---|
| Founded | 1870 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | N/A | 2020 |
| Metric | TNC | RLAY |
|---|---|---|
| Price | $79.60 | $7.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $102.00 | $16.00 |
| AVG Volume (30 Days) | 99.6K | ★ 2.1M |
| Earning Date | 02-17-2026 | 02-25-2026 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.91 | N/A |
| Revenue | ★ $1,240,800,000.00 | $8,355,000.00 |
| Revenue This Year | N/A | $19.96 |
| Revenue Next Year | $5.63 | N/A |
| P/E Ratio | $27.37 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $67.32 | $1.78 |
| 52 Week High | $90.44 | $9.04 |
| Indicator | TNC | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 59.74 | 44.76 |
| Support Level | $76.88 | $7.01 |
| Resistance Level | $80.50 | $7.84 |
| Average True Range (ATR) | 1.79 | 0.45 |
| MACD | 0.28 | -0.10 |
| Stochastic Oscillator | 88.11 | 35.45 |
Tennant Co is a manufacturer of floor cleaning equipment, wood flooring, and wood products. It operates in four geographic business units including North America; Latin America; Europe, Middle East, Africa; and Asia Pacific. The company offers products and solutions consisting of mechanized cleaning equipment, detergent-free, and other sustainable cleaning technologies, aftermarket parts and consumables, equipment maintenance and repair service, specialty surface coatings, and business solutions such as financing, rental and leasing programs, and machine-to-machine asset management solutions.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).